New York City-based pharmaceutical company Pfizer Inc is planning on investing $600 million in biotechnology and other emerging growth companies through Pfizer Ventures. About 25 percent of the funding will focus on neuroscience.
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle. In addition to increased funding, Pfizer will extend its leadership as a venture capital investor with an expanded team that leverages expertise across venture capital investing, business development, drug discovery and clinical development.
